Behavioral Pharmacology Overview

Principles

Definition

Behavioral pharmacology is an interdisciplinary field of research that investigates the effects of pharmacological agents on behavior. It focuses on understanding the complex relationship between drug action at biological levels and observable behavioral outcomes in organisms, often exploring underlying neural mechanisms and their implications for therapeutic and toxicological effects.

Ontological type

Neural Mechanisms

Core Experimental Methods

Clinical Applications

Key developments

Key Figures

Foundational Psychopharmacology era

Urban Ungerstedt [1] is a foundational figure in psychopharmacology, with affiliations at Karolinska Institutet [3] and the University of Pittsburgh [4] during the Foundational Psychopharmacology era. His key contribution, demonstrated by the 1971 paper Postsynaptic Supersensitivity after 6-Hydroxy-dopamine Induced Degeneration of the Nigro-striatal Dopamine System [6], helped quantify receptor- and dopaminergic-system changes underlying behavior and established critical dose-response links in a mechanistic framework. Tomas Hökfelt [2] is another central figure of the era, with affiliations at Karolinska Institutet [3] and Heidelberg University [5], whose experimental work informed receptor-centric interpretations of catecholaminergic signaling. His notable contribution, as captured by Evidence for dopamine receptor stimulation by apomorphine [7] (1967), helped cement dopamine receptor pharmacology as a mechanistic basis for behavior, a cornerstone of this era.

Reinforcement and Sensitization era

Jacqueline N. Crawley [1], associated with Yale University [3] and Menlo School [4], was an active figure in behavioral pharmacology during the Reinforcement and Sensitization era. Her key contribution, exemplified by the 1980 Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines [6], helped establish standardized assays to probe how anxiety-related states interact with reinforcement mechanisms in this era. G. Di Chiara [2], based at the University of Cagliari [5], made pivotal contributions to understanding intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens, as reported in Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens [7]. This shell–core distinction, highlighted by the 1995 study [7], linked dopamine signaling to incentive value and relapse vulnerability, guiding reinforcement-focused addiction models in this era.

Circuit and Memory Pharmacology era

Kent Berridge [1], affiliated with University of California, San Diego [3] and University of California, Los Angeles [4], is a central figure in the behavioral pharmacology of motivation and memory during this era. His key contributions include articulating the incentive-sensitization theory of addiction in The psychology and neurobiology of addiction: an incentive–sensitization view [8] and developing Liking, wanting, and the incentive-sensitization theory of addiction [7], which reframed addiction around incentive salience and the dissociation of 'liking' from 'wanting' to explain relapse [7]. Terry E. Robinson [2], linked to Rockefeller University [5] and Stanford University [6], contributed to the incentive-sensitization framework paper [7], advancing empirical testing of the theory and its relevance to relapse and motivated behavior. This work helped translate circuit- and memory-focused pharmacology into strategies to reduce relapse by modulating incentive salience and memory reconsolidation processes, as outlined in the incentive-sensitization framework paper [7].